Intelligent Bio Solutions Inc. Common Stock (INBS)

FairStock Score: 49/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham-style investor, I look first for a business that earns money and needs little capital. Intelligent Bio Solutions does not yet meet that test. In fiscal 2026, the year ended 2026-06-30, revenue was $4.2 million, up from $3.1 million in fiscal 2025, but the net loss widened to $12.4 million from $10.6 million. Diluted EPS was -$8.44 in fiscal 2026, and the latest filed quarter, fiscal Q3 2026 ended 2026-03-31, showed $1.1 million of revenue and a $2.9 million net loss. That is not a profitable enterprise; it is a promising idea still consuming cash. FairStock calculations at the 2026-10-13 close of $1.48 show a negative P/E of -0.18, P/B of 0.78, ROE of -307.69%, ROCE of -76.20%, and a trailing free cash flow yield of -269.0%. Piotroski is 2/9 and Altman Z is -9.17, both pointing to financial weakness. The balance sheet has D/E of 0.34, which is not high, but cash burn of about $12.1 million against a $4.5 million market cap is severe. FairStock's revenue growth figure of 35.78% is a positive, but profit growth of -26.46% means the losses are growing. The Lynch category is none because the company has lost money in each of the last four years. The product—fingerprint sweat analysis for drug screening—could have a niche, but with $4.2 million of revenue and 59 employees, there is no clear moat yet. Valuation looks optically cheap on P/B, but book value can vanish with continued losses. I would need evidence of durable revenue, narrowing losses, and self-funding cash flow before calling this a sound value.

In plain English: Intelligent Bio Solutions sells a fingerprint-based drug screening system. The business is very small and losing money, with sales of $4.2 million in fiscal 2026 against a $12.4 million net loss, so it looks financially weak. At $1.48, the stock may look cheap next to some of its reported numbers, but the losses and cash burn make that cheapness hard to trust.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer